[1] A. Scalbert, G. Williamson, Dietary intake and bioavailability of polyphenols, J. Nutr. 130 (2000) 2073S–2085S, https://doi.org/10.1093/jn/130.8.2073S.
[2] S. Ramos, Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways, Mol. Nutr. Food Res. 52 (2008) 507–526, https://doi.org/10. 1002/mnfr.200700326.
[3] B. Sultana, F. Anwar, Flavonols (kaempeferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants, Food Chem. 108 (2008) 879–884, https://doi.org/10.1016/j.foodchem.2007.11.053.
[4] S. Kumar, A.K. Pandey, Chemistry and biological activities of flavonoids: an over- view, Sci. World J. (2013) 162750, https://doi.org/10.1155/2013/162750 2013.
[5] A. Massi, O. Bortolini, D. Ragno, T. Bernardi, G. Sacchetti, M. Tacchini, C. De Risi, Research progress in the modification of quercetin leading to anticancer agents, Molecules 22 (2017) 1270, https://doi.org/10.3390/molecules22081270.
[6] A. Rauf, M. Imran, I.A. Khan, M. ur-Rehman, S.A. Gilani, Z. Mehmood, M.S. Mubarak, Anticancer potential of quercetin: a comprehensive review, Phytother Res. 32 (2018) 2109–2130, https://doi.org/10.1002/ptr.6155.
[7] A.V. Anand David, R. Arulmoli, S. Parasuraman, Overviews of biological im- portance of quercetin: a bioactive flavonoid, Phcog. Rev. 10 (2016) 84–89, https:// doi.org/10.1155/2013/162750.
[8] D. Xu, M.J. Hu, Y.Q. Wang, Y.L. Cui, Antioxidant activities of quercetin and its complexes for medicinal application, Molecules 24 (2019) 1123, https://doi.org/ 10.3390/molecules24061123.
[9] J. Terao, Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function, Biochem. Pharmacol. 139 (2017) 15–23, https://doi.org/10.1016/j.bcp.2017.03.021.
[10] P. Knekt, J. Kumpulainen, R. Järvinen, H. Rissanen, M. Heliövaara, A. Reunanen, T. Hakulinen, A. Aromaa, Flavonoid intake and risk of chronic diseases, Am. J. Clin. Nutr. 76 (2002) 560–568, https://doi.org/10.1093/ajcn/76.3.560.
[11] J.M. Llovet, J. Zucman-Rossi, E. Pikarsky, B. Sangro, M. Schwartz, M. Sherman, G. Gores, Hepatocellular carcinoma, Nat. Rev. Dis. Primers. 2 (2016) 16018, https://doi.org/10.1038/nrdp.2016.18.
[12] J. Bruix, G.J. Gores, V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut 63 (2014) 844–855, https://doi.org/10.1136/gutjnl-2013-306627.
[13] J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D.M. Parkin, M. Piñeros, A. Znaor, F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int. J. Canc. 144 (2019) 1941–1953, https://doi. org/10.1002/ijc.31937.
[14] M. Natsuizaka, T. Omura, T. Akaike, Y. Kuwata, K. Yamazaki, T. Sato, Y. Karino, J. Toyota, T. Suga, M. Asaka, Clinical features of hepatocellular carcinoma with extrahepatic metastases, J. Gastroenterol. Hepatol. 11 (2005) 1781–1787, https:// doi.org/10.1111/j.1440-1746.2005.03919.x.
[15] D.B. Sneag, K. Krajewski, A. Giardino, K.N. O'Regan, A.B. Shinagare, J.P. Jagannathan, N. Ramaiya, Extrahepatic spread of hepatocellular carcinoma: spectrum of imaging findings, AJR Am. J. Roentgenol. 197 (2011) W658–W664, https://doi.org/10.2214/AJR.10.6402.
[16] C. Toso, G. Mentha, P. Majno, Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence, Am. J. Transplant. 11 (2011) 2031–2035, https:// doi.org/10.1111/j.1600-6143.2011.03689.x.
[17] Y. Zhang, Z.L. Shi, X. Yang, Z.F. Yin, Targeting of circulating hepatocellular car- cinoma cells to prevent postoperative recurrence and metastasis, World J. Gastroenterol. 20 (2014) 142–147, https://doi.org/10.3748/wjg.v20.i1.142.
[18] L. Zender, A. Villanueva, V. Tovar, D. Sia, D.Y. Chiang, J.M. Llovet, Cancer gene discovery in hepatocellular carcinoma, J. Hepatol. 52 (2010) 921–929, https://doi. org/10.1016/j.jhep.2009.12.034.
[19] J. Muntané, A.J. De la Rosa, F. Docobo, R. García-Carbonero, F.J. Padillo, Targeting tyrosine kinase receptors in hepatocellular carcinoma, Curr. Cancer Drug Targets 13 (2013) 300–312, https://doi.org/10.2174/15680096113139990075.
[20] K. Matsumoto, M. Umitsu, D.M. De Silva, A. Roy, D.P. Bottaro, Hepatocyte growth factor/MET in cancer progression and biomarker discovery, Canc. Sci. 108 (2017) 296–307, https://doi.org/10.1111/cas.13156.
[21] L.X. Qin, Z.Y. Tang, The prognostic molecular markers in hepatocellular carcinoma, World J. Gastroenterol. 8 (2002) 385–392, https://doi.org/10.3748/wjg.v8.i2.193.
[22] P. Huang, X. Xu, L. Wang, B. Zhu, X. Wang, J. Xia, The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment, J. Cell Mol. Med. 18 (2014) 218–230, https://doi.org/10.1111/jcmm.12153.
[23] K. Jaskiewicz, M.R. Chasen, Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis, Anticancer Res. 15 (1995) 559–562.
[24] L. Goyal, M.D. Muzumdar, A.X. Zhu, Targeting the HGF/c-MET pathway in hepa- tocellular carcinoma, Clin. Canc. Res. 19 (2013) 2310–2318, https://doi.org/10. 1158/1078-0432.CCR-12-2791.
[25] R. Matsushima-Nishiwaki, H. Toyoda, R. Takamatsu, E. Yasuda, S. Okuda, A. Maeda, Y. Kaneoka, N. Yoshimi, T. Kumada, O. Kozawa, Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the sup- pression of the phosphoinositide 3-kinase (PI3K)/AKT pathway, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1863 (2017) 1629–1639, https://doi.org/10.1016/j. bbadis.2017.04.021.
[26] R. Matsushima-Nishiwaki, N. Yamada, K. Fukuchi, O. Kozawa, Sphingosine 1- phosphate (S1P) reduces hepatocyte growth factor-induced migration of hepato- cellular carcinoma cells via S1P receptor 2, PloS One 13 (2018) e0209050, , https:// doi.org/10.1371/journal.pone.0209050.
[27] R. Matsushima-Nishiwaki, H. Toyoda, T. Nagasawa, E. Yasuda, N. Chiba, S. Okuda, A. Maeda, Y. Kaneoka, T. Kumada, O. Kozawa, Phosphorylated heat shock protein 20 (HSPB6) regulates transforming growth factor-α-induced migration and invasion of hepatocellular carcinoma cells, PloS One 11 (2016) e0151907, , https://doi.org/ 10.1371/journal.pone.0151907.
[28] N. Yamada, R. Matsushima-Nishiwaki, A. Masue, K. Taguchi, O. Kozawa, Olive oil polyphenols suppress the TGF-α-induced migration of hepatocellular carcinoma cells, Biomed. Rep. 1 (2019) 1–5, https://doi.org/10.3892/br.2019.1215.
[29] M. Li, J. Chen, X. Yu, S. Xu, D. Li, Q. Zheng, Y. Yin, Myricetin suppresses the propagation of hepatocellular carcinoma via down-regulating expression of YAP, Cells 8 (2019) 358, https://doi.org/10.3390/cells8040358.
[30] H. Nakabayashi, K. Taketa, K. Miyano, T. Yamane, J. Sato, Growth of human he- patoma cell lines with differentiated functions in chemically defined medium, Canc. Res. 42 (1982) 3858–3863 doi: Published September 1982.
[31] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227 (1970) 680–685, https://doi.org/10.1038/ 227680a0.
[32] J.J. Hoffmann, J.R. Cole, Phytochemical investigation of Adenium obesum Forskal (Apocynaceae): isolation and identification of cytotoxic agents, J. Pharmaceut. Sci. 66 (1977) 1336–1338, https://doi.org/10.1002/jps.2600660935.
[33] K. Breuhahn, T. Longerich, P. Schirmacher, Dysregulation of growth factor sig- naling in human hepatocellular carcinoma, Oncogene 25 (2006) 3787–3800, https://doi.org/10.1038/sj.onc.1209556.
[34] C.J. Vlahos, W.F. Matter, K.Y. Hui, R.F. Brown, A specific inhibitor of phosphati- dylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), J. Biol. Chem. 269 (1994) 5241–5248.
[35] H. Hayashi, Y. Nishioka, S. Kamohara, F. Kanai, K. Ishii, Y. Fukui, F. Shibasaki, T. Takenawa, H. Kido, N. Katsunuma, Y. Ebina, The α-type 85-kDa subunit of phosphatidylinositol 3-kinase is phosphorylated at tyrosines 368, 580, and 607 by the insulin receptor, J. Biol. Chem. 268 (1993) 7107–7117.
[36] M. Tu, Y. Li, C. Zeng, Z. Deng, S. Gao, W. Xiao, W. Luo, W. Jiang, L. Li, G. Lei, MicroRNA-127-5p regulates osteopontin expression and osteopontin-mediated proliferation of human chondrocytes, Sci. Rep. 6 (2016) 25032, https://doi.org/10. 1038/srep25032.
[37] G. Giannelli, P. Koudelkova, F. Dituri, W. Mikulits, Role of epithelial to mesench- ymal transition in hepatocellular carcinoma, J. Hepatol. 65 (2016) 798–808, https://doi.org/10.1016/j.jhep.2016.05.007.
[38] B.N. Smith, N.A. Bhowmick, Role of EMT in metastasis and therapy resistance, J. Clin. Med. 5 (2016), https://doi.org/10.3390/jcm5020017 pii: E17.
[39] J.L. Huang, S.W. Cao, Q.S. Ou, B. Yang, S.H. Zheng, J. Tang, J. Chen, Y.W. Hu, L. Zheng, Q. Wang, The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepato- cellular carcinoma, Mol. Canc. 17 (2018) 93, https://doi.org/10.1186/s12943-018- 0841-x.
[40] H. Zou, Y. Zheng, W. Ge, S. Wang, X. Mou, Synergistic anti-tumour effects of quercetin and oncolytic adenovirus expressing TRAIL in human hepatocellular carcinoma, Sci. Rep. 8 (2018) 2182, https://doi.org/10.1038/s41598-018-20213-7.
[41] Y. Ji, L. Li, Y.X. Ma, W.T. Li, L. Li, H.Z. Zhu, M.H. Wu, J.R. Zhou, Quercetin inhibits growth of hepatocellular carcinoma by apoptosis induction in part via autophagy stimulation in mice, J. Nutr. Biochem. 69 (2019) 108–119, https://doi.org/10. 1016/j.jnutbio.2019.03.018.
[42] R. Wang, H. Zhang, Y. Wang, F. Song, Y. Yuan, Inhibitory effects of quercetin on the progression of liver fibrosis through the regulation of NF-кB/IкBα, p38 MAPK, and Bcl-2/Bax signaling, Int. Immunopharm. 47 (2017) 126–133, https://doi.org/10. 1016/j.intimp.2017.03.029.
[43] I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-kinase-AKT pathway in human cancer, Nat. Rev. Canc. 2 (2002) 489–501, https://doi.org/10.1038/nrc839.
[44] Y. Chen, B.C. Wang, Y. Xiao, PI3K: a potential therapeutic target for cancer, J. Cell. Physiol. 227 (2012) 2818–2821, https://doi.org/10.1002/jcp23038.
[45] F. Fang, T. Song, T. Zhang, Y. Cui, G. Zhang, Q. Xiong, MiR-425-5p promotes in- vasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways, Oncotarget 8 (2017) 31745–31757, https://doi.org/10.18632/oncotarget.15958.
[46] Y. Han, M. Chen, A. Wang, X. Fan, STAT3-induced upregulation of lncRNA CASC11 promotes the cell migration, invasion and epithelial-mesenchymal transition in hepatocellular carcinoma by epigenetically silencing PTEN and activating PI3K/ AKT signaling pathway, Biochem. Biophys. Res. Commun. 508 (2019) 472–479, https://doi.org/10.1016/j.bbrc.2018.11.092.
[47] R. Mayoral, A. Fernández-Martínez, L. Boscá, P. Martin-Sanz, Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells, Carcinogenesis 26 (2005) 753–761, https://doi.org/10.1093/carcin/bgi022.
[48] W.H. Hsu, H.L. Chiou, C.L. Lin, S.H. Kao, H.L. Lee, C.J. Liu, Y.H. Hsieh, Metastasis- associated protein 2 regulates human hepatocellular carcinoma metastasis pro- gression through modulating p38MAPK/MMP pathways, J. Canc. 10 (2019) 6716–6725, https://doi.org/10.7150/jca.35626.
[49] L. Wu, J. Li, T. Liu, S. Li, J. Feng, Q. Yu, J. Zhang, J. Chen, Y. Zhou, J. Ji, K. Chen, Y. Mao, F. Wang, W. Dai, X. Fan, J. Wu, C. Guo, Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway, Cancer Med. 8 (2019) 4806–4820, https://doi.org/10.1002/cam4.2388.
[50] R. Zamora-Ros, V. Fedirko, A. Trichopoulou, C.A. González, C. Bamia, E. Trepo, U. Nöthlings, T. Duarte-Salles, M. Serafini, L. Bredsdorff, K. Overvad, A. Tjønneland, J. Halkjær, G. Fagherazzi, F. Perquier, M.-C. Boutron-Ruault, V. Katzke, A. Lukanova, A. Floegel, H. Boeing, P. Lagiou, D. Trichopoulos, C. Saieva, C. Agnoli, A. Mattiello, R. Tumino, C. Sacerdote, H.B. Bueno-de-Mesquita, P.H.M. Peeters, E. Weiderpass, D. Engeset, G. Skeie, M.V. Argüelles, E. Molina- Montes, M. Dorronsoro, M.J. Tormo, E. Ardnaz, U. Ericson, E. Sonestedt, M. Sund, R. Landberg, K.-T. Khaw, N.J. Wareham, F.L. Crowe, E. Riboli, M. Jenab, Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European prospective investigation into cancer and nutrition study, Int. J. Canc. 133 (2013) 2429–2443, https://doi.org/10.1002/ijc.28257.
[51] L. Jia, S. Huang, X. Yin, Y. Zan, Y. Guo, L. Han, Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated au- tophagy induction, Life Sci. 208 (2018) 123–130, https://doi.org/10.1016/j.lfs. 2018.07.027.
[52] F.A. Bhat, G. Sharmila, S. Balakrishnan, R. Arunkumar, P. Elumalai, S. Suganya, P. Raja Singh, N. Srinivasan, J. Arunakaran, Quercetin reverses EGF-induced epi- thelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway, J. Nutr. Biochem. 25 (2014) 1132–1139, https:// doi.org/10.1016/j.jnutbio.2014.06.008.